1. Scrip
  2. >>Business
  3. >>Deals

J&J Makes Its Biggest Bet Yet On Antibody-Drug Conjugates With Ambrx Buyout

 
• By Alaric DeArment

CEO Joaquin Duato told the J.P. Morgan Healthcare Conference that the drug maker hopes the $2bn acquisition can make one of its lead candidates, ARX517, the first PSMA-directed ADC for prostate cancer.

J&J CEO Joaquin Duato spoke about the company's acquisition of Ambrx at the J.P. Morgan Healthcare Conference • Source: Shutterstock

Johnson & Johnson is beginning 2024 by making another bet on antibody-drug conjugates (ADCs) with the acquisition of Ambrx Biopharma, Inc., which the drug maker announced shortly before CEO Joaquin Duato spoke in a fireside chat at the J.P. Morgan Healthcare Conference.

J&J announced on 8 January that it will take over Ambrx for about $2bn in an all-cash merger

Key Takeaways

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

More from Business